Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

This project is a prospective, open-label, randomized controlled clinical study. It plans to enroll 60 patients with unresectable HCC and no distant metastasis, randomly assigned to the experimental group and the control group, with 30 cases in each group. The experimental group was treated with radiotherapy combined with immunotherapy and Bevacizumab, while the control group was treated with immunotherapy and Bevacizumab. The efficacy of the patients and the conversion rate to surgery were evaluated.

NCT Number	NCT07179900
Lead Sponsor	Hebei Medical University Fourth Hospital
Conditions	Hepatocellular Carcinoma
Enrollment	60 participants
Start Date	2025-03-01
Primary Completion	2027-12 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-03